RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

被引：1

作者：

Cherny, Nathan I. ^{[1
]}

Dafni, Urani ^{[2
,3
]}

Bogaerts, Jan ^{[4
]}

Latino, Nicola J. ^{[5
]}

Pentheroudakis, George ^{[6
]}

Douillard, Jean-Yves ^{[5
]}

Tabernero, Josep ^{[7
,8
]}

Zielinski, Christoph ^{[9
]}

Piccart, Martine J. ^{[10
]}

de Vries, Elisabeth G. E. ^{[11
]}

机构：

[1] Shaare Zedek Med Ctr, Dept Med Oncol, Canc Pain & Palliat Med Serv, IL-91031 Jerusalem, Israel

[2] Univ Athens, Lab Biostat, Sch Hlth Sci, Athens, Greece

[3] Frontier Sci Fdn Hellas, Athens, Greece

[4] EORTC Headquarters, Methodol Direct, Brussels, Belgium

[5] ESMO Head Off, Lugano, Switzerland

[6] Ioannina Univ Hosp, Med Oncol Dept, Ioannina, Greece

[7] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[8] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain

[9] Med Univ Vienna, Div Oncol, Vienna, Austria

[10] Univ Libre Bruxelles, Jules Bordet Inst, Brussels, Belgium

[11] Univ Groningen, Dept Med Oncol, Univ Med Ctr Groningen, Groningen, Netherlands

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2018年 / 110卷 / 10期

关键词：

ESMO-MAGNITUDE; SCALE;

D O I：

10.1093/jnci/djy029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[31] Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical RecommendationsS
Yu, Jingjing
Wang, Yan
Ragueneau-Majlessi, Isabelle
[J]. DRUG METABOLISM AND DISPOSITION, 2022, 50 (01) : 1 - 7
[32] Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
Parikh, Ravi B. B.
Hubbard, Rebecca A. A.
Wang, Erkuan
Royce, Trevor J. J.
Cohen, Aaron B. B.
Clark, Amy S. S.
Mamtani, Ronac
[J]. JAMA ONCOLOGY, 2023, 9 (04) : 567 - 569
[33] Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Gizem Kayki-Mutlu
Zinnet Sevval Aksoyalp
Leszek Wojnowski
Martin C. Michel
[J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 383 - 383
[34] Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
Sang, Angela
Zhuo, Selena
Bochanis, Adara
Manautou, Jose E.
Bahal, Raman
Zhong, Xiao-bo
Rasmussen, Theodore P.
[J]. BIODRUGS, 2024, 38 (04) : 511 - 526
[35] Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2017
Yu, Jingjing
Petrie, Ichiko D.
Levy, Rene H.
Ragueneau-Majlessi, Isabelle
[J]. DRUG METABOLISM AND DISPOSITION, 2019, 47 (02) : 135 - 144
[36] An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
Chen, Emerson Y.
Raghunathan, Vikram
Prasad, Vinay
[J]. JAMA INTERNAL MEDICINE, 2019, 179 (07) : 915 - 921
[37] Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
Michaeli, Thomas
Michaeli, Daniel Tobias
[J]. VALUE IN HEALTH, 2024, 27 (04) : 449 - 457
[38] Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015
Bujosa Rodriguez, A.
Tapia, J. C.
Hwang, T.
Molto Valiente, C.
Templeton, A. J.
Barnadas, A.
Amir, E.
Tibau, A.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[39] Update on Novel Drugs for Primary Care Practice: Drugs Approved by the US Food and Drug Administration in 2015
Smetana, Gerald W.
[J]. ANNALS OF INTERNAL MEDICINE, 2016, 164 (09) : W48 - W54
[40] Role of US military research programs in the development of US Food and Drug Administration - Approved antimalarial drugs
Kitchen, LW
Vaughn, DW
Skillman, DR
[J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) : 67 - 71

← 1 2 3 4 5 →